You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKesson
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Poziotinib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Poziotinib?

Poziotinib is an investigational drug.

There have been 18 clinical trials for Poziotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2013.

The most common disease conditions in clinical trials are Breast Neoplasms, Adenocarcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, and National OncoVenture.

There are six US patents protecting this investigational drug and one hundred and seventeen international patents.

Recent Clinical Trials for Poziotinib
TitleSponsorPhase
Study of Poziotinib in Japanese Patients With NSCLCSpectrum Pharmaceuticals, IncPhase 1/Phase 2
Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male SubjectsSpectrum Pharmaceuticals, IncPhase 1
A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced MalignanciesSpectrum Pharmaceuticals, IncPhase 2

See all Poziotinib clinical trials

Clinical Trial Summary for Poziotinib

Top disease conditions for Poziotinib
Top clinical trial sponsors for Poziotinib

See all Poziotinib clinical trials

US Patents for Poziotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Poziotinib   Start Trial Amide derivative for inhibiting the growth of cancer cells Hanmi Holdings Co., Ltd. (Seoul, KR)   Start Trial
Poziotinib   Start Trial Method for EGFR directed combination treatment of non-small cell lung cancer Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Poziotinib   Start Trial Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pi- peridin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein Hanmi Science Co., Ltd (Hwaseong-si, KR)   Start Trial
Poziotinib   Start Trial Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pi- peridin-1-yi)prop-2-en-1-one Hanmi Pharm. Co., Ltd. (Gyeonggi-do, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Poziotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Poziotinib Argentina 066876 2027-06-05   Start Trial
Poziotinib Argentina 110003 2027-06-05   Start Trial
Poziotinib Australia 2008260772 2027-06-05   Start Trial
Poziotinib Brazil PI0811069 2027-06-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Mallinckrodt
Baxter
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.